- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01545284
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis
July 23, 2014 updated by: Innovaderm Research Inc.
This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .
Study Overview
Detailed Description
Patients will receive acitretin once daily for a maximum of 24 weeks.
Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study.
Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24.
The starting dose will be 10mg/day and, if well tolerated, will be increased in the first 4 weeks to a maximum of 30 mg/day.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Windsor, Ontario, Canada, N8W 5L7
- Windsor Clinical Research Inc.
-
-
Quebec
-
Montreal, Quebec, Canada, H2K 4L5
- Innovaderm Research Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or post-menopausal or surgically sterile women, 18 years of age or older at time of consent
- Has stable chronic hand dermatitis for at least 6 months
- Has chronic hand dermatitis with a PGA of severe at Day 0
- Unless vasectomized for at least 6 months or clinically diagnosed infertile, if male patient has a female partner of childbearing potential, patient and patient's partner are willing to use effective contraceptive method for at least 30 days before screening and until 2 years after the study. Male patient should not father a child or donate sperm during the study and for 2 years after the last treatment.
Effective contraceptive methods are:
- Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream
- Female partner: Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo-Provera, Evra and Nuvaring. Oral contraceptives must have been taken at a stable dose for at least 90 days before study start
Female partner: Intrauterine device (IUD)
- Female patient has a negative serum pregnancy test within 14 days of Day 0
- Capable of giving informed consent and the consent must be obtained prior to any study related procedures.
Exclusion Criteria:
- Female of childbearing potential, pregnant or lactating
- Has any other skin disease that could impair his/her safety during the study or interfere with the evaluation of the results
- Has a known allergy to acitretin, other retinoids or vitamin A derivates, or to any component of the study product
- Has used acitretin within 24 weeks of Day 0
- Has used systemic retinoid (including alitretinoin) within 6 months of Day 0
- Has used tetracycline or other vitamin supplements containing vitamin A within 4 weeks of Day 0
- Has used methotrexate within 6 months of Day 0
- Has used systemic therapy (e.g. corticosteroids, immunosuppressants or phototherapy) within four weeks of Day 0. Inhaled corticosteroids for stable medical conditions are allowed
- Has used any topical treatment for had dermatitis (e.g. retinoids, corticosteroids, tacrolimus, pimecrolimus) on the hands within 14 days of Day 0. If patients are using topical treatments for dermatitis on other areas of the body, it must be applied with gloves.
- Has used investigational agent within 30 days prior to Day 0, or within 5 half-lives of the investigational agent prior to day 0 (whichever is longer)
- Has a history of alcoholism or drug abuse within 12 months prior to Day 0
- Is planning to donate blood within 2 years after the end of the study
- Clinically significant increase in hepatic enzymes, cholesterol or triglyceride at screening that would, in the opinion of the investigator, put patient at risk if he/she receives acitretin
- Diagnosis or symptoms of inflammatory bowel diseases at screening or baseline
- Has an unstable or serious medical condition as defined by the investigator or presence of any significant medical condition, including severe renal impairment, that might cause this study to be detrimental to the patient
- Diagnosis or symptoms of active depression, including depression currently under control with medication, at screening or baseline
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Acitretin
Patients will receive acitretin once daily for a maximum of 24 weeks.
Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study.
Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24.
The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
|
All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose.
If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day.
Patients will be instructed to take the treatment as a single oral dose with a meal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients who reach a Physician Global Assessment (PGA) of clear or almost clear at the end of therapy.
Time Frame: 12-24 weeks
|
12-24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients who reach a partial response defined as a PGA of clear, almost clear or mild at the end of therapy
Time Frame: 12-24 weeks
|
12-24 weeks
|
Change from baseline in modified Total Lesion Symptom Score (mTLSS) at the end of therapy
Time Frame: 12-24 weeks
|
12-24 weeks
|
Mean time to response defined as the number of days between baseline and the time the patient reaches a PGA of clear or almost clear
Time Frame: 24 weeks
|
24 weeks
|
Mean Patient Global Assessment (PaGA) at the end of therapy
Time Frame: 12-24 weeks
|
12-24 weeks
|
Change from baseline in extent of disease at the end of therapy
Time Frame: 12-24 weeks
|
12-24 weeks
|
Type, severity and relationship of adverse events
Time Frame: 12-24 weeks
|
12-24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Jerry Tan, MD, FRCPC, Windsor Clinical Research Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
January 1, 2014
Study Completion (ACTUAL)
January 1, 2014
Study Registration Dates
First Submitted
February 29, 2012
First Submitted That Met QC Criteria
February 29, 2012
First Posted (ESTIMATE)
March 6, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
July 24, 2014
Last Update Submitted That Met QC Criteria
July 23, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Inno-6022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hand Dermatitis
-
University Hospital, Gentofte, CopenhagenTrygFonden, DenmarkCompletedChronic Hand Dermatitis | Chronic Hand EczemaDenmark
-
HenKan Pharmaceutical Co., Ltd.Completed
-
George Washington UniversityCelgene CorporationWithdrawnChronic Hand DermatitisUnited States
-
NovartisCompleted
-
University of RochesterIncyte CorporationActive, not recruiting
-
Asana BioSciencesCompletedChronic Hand DermatitisUnited States, Canada
-
University Hospital, ToulouseRecruiting
-
LEO PharmaRecruiting
-
The Center for Clinical and Cosmetic ResearchAfecta PharmaceuticalsCompletedHand DermatitisUnited States
-
National Jewish HealthCompletedHand DermatitisUnited States
Clinical Trials on Acitretin
-
Frankel, Amylynne, M.D.Stiefel, a GSK CompanyUnknownPsoriasisUnited States
-
Xijing HospitalHenan Provincial People's Hospital; The First Affiliated Hospital of Dalian...Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedNon-melanomatous Skin CancerUnited States
-
Cairo UniversityRecruitingDepression | Liver Diseases | Hyperlipidemias | XerosisEgypt
-
Istituti Fisioterapici OspitalieriUniversity of BolognaCompleted
-
Günther HofbauerUniversity of ZurichWithdrawn
-
South Valley UniversityCompleted
-
South Valley UniversityActive, not recruiting
-
University of Medicine and Dentistry of New JerseyConnetics Corp.CompletedPsoriasis
-
PfizerCompletedModerate to Severe PsoriasisKorea, Republic of